^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CXCL13 elevation

    i
    Other names: CXCL13, ANGIE, ANGIE2, BCA-1, BLC, BLR1L, SCYB13, Chemokine (C-X-C motif) ligand 13
    Entrez ID:
    10563
    Related biomarkers:
    Expression
    Mutation
    1year
    A Beyond T Cell Toxicity - Intrathecal Cxcl13 Elevation Indicates B-Cell Involvement In Neurological Immune-Related Adverse Events Following Immune Checkpoint Inhibition: 2 Case Observations And Comprehensive Review (EANO 2023)
    Case 1: A 75y female with metastatic melanoma developed double vision & general weakness 2 weeks after the 1st cycle of ipilimumab & nivolumab...Case 2: A 75y female with metastatic invasive enteric adenocarcinoma of the lung developed gait ataxia & ataxia of the lower limbs 5 months after pembrolizumab therapy... Intrathecal CXCL13 may serve as diagnostic tool of B cell involvement, here supported by intrathecal immunoglobulin synthesis, presence of plasma cells and/or severely altered immune cell compositions. Early treatment escalation with B cell depleting agents such as rituximab may help prevent fatal clinical courses.
    Clinical • Review • Adverse events • Checkpoint inhibition
    |
    CD8 (cluster of differentiation 8) • TTN (Titin) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CXCL13 elevation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Rituxan (rituximab)